IGF-1 LR3

Identity: what LR3 means

Long R3 IGF-I is a recombinant analogue of human insulin-like growth factor I, not a synonym for every IGF-1 product. The original engineering paper describes a complete 70-amino-acid human IGF-I domain with two deliberate changes: a 13-amino-acid N-terminal extension and replacement of glutamate with arginine at position 3 of the IGF-I domain (Glu3 → Arg3). The resulting molecule has 83 amino acids.

The NMR structure deposited as PDB 3LRI confirms that identity and sequence. A later LC-MS characterization described the reviewed analogue as 9,110 Da. That value characterises the defined recombinant molecule; it does not authenticate an untested retail vial or every material sold under the abbreviation “LR3”.

Why it was engineered

Circulating and locally produced IGF-binding proteins (IGFBPs) regulate how much IGF-I is free to reach receptors. The LR3 changes greatly reduce binding to several IGFBPs while retaining activity at the type-1 IGF receptor (IGF-1R). This is why LR3 became useful as an experimental reagent and as a growth supplement in serum-free mammalian cell culture.

“More potent” is not a universal property. In the original 1992 experiments, Long [Arg3] IGF-I was more potent than native IGF-I in cell systems that secreted IGFBPs, but less potent in chicken embryo fibroblasts without detectable IGFBP secretion. The result supports an IGFBP-dependent mechanism; it does not prove a fixed twofold advantage in people or a general muscle-building effect.

Evidence landscape: no human intervention study identified

The reviewed literature contains structural work, receptor and cell-culture experiments, and studies in rats, guinea pigs, pigs, calves and other animal models. A ClinicalTrials.gov exact-phrase query for “Long R3 IGF-I” returned 0 studies on 28 July 2026. A second exact query for “IGF-1 LR3” also returned 0.

Accordingly, no registered human intervention study was identified for the exact 83-amino-acid LR3 analogue. “Humans” indexing on a cell paper can refer to human-derived cell lines and must not be described as administration to human participants. Evidence for native IGF-1 or mecasermin is also not LR3 clinical evidence.

What the animal and cell studies show

The preclinical results are biologically active but inconsistent with a simple hypertrophy narrative:

• in cell culture, LR3 activates IGF-1R and can support proliferation or survival, with potency depending on the cell system and its IGFBPs;
• in pregnant rats, radiolabelled LR3IGF-I cleared from plasma faster than native IGF-I and circulated mainly as free peptide;
• in guinea pigs, a seven-day infusion increased the relative weights of several organs but did not improve overall body-weight gain or carcass composition;
• in pigs, acute LR3 exposure produced a stronger and more prolonged glucose-lowering effect than native IGF-I despite faster circulation clearance;
• in a separate four-day pig study, LR3 reduced feed intake and average daily gain and suppressed several endocrine measurements.

These results show that receptor activity, plasma residence time, glucose effects and whole-animal growth are separate outcomes. They do not establish new muscle-cell formation, predictable hypertrophy or athletic benefit in humans.

Pharmacokinetic and safety limits

No validated human pharmacokinetic study of the exact LR3 analogue was found. The frequently repeated 20–30-hour half-life is therefore not a human fact established by the reviewed sources. The rat tracer study points in the opposite direction for plasma clearance: reduced IGFBP binding was associated with faster removal and more breakdown products.

Duration of a biological effect is not the same as plasma half-life. In pigs, glucose suppression lasted longer than with native IGF-I even though the variants cleared more rapidly. That animal observation supports a plausible hypoglycaemic hazard signal, not a safe dosing interval for people.

Product-specific human adverse-event rates, immunogenicity, interaction risks, organ effects and long-term carcinogenic risk remain unknown. The Increlex label documents risks for mecasermin, but it is not an LR3 safety label and cannot fill those gaps.

Regulatory and anti-doping status

The European Commission’s Union Register dataset dated 27 July 2026 returned no match for “IGF-1 LR3” or “Long R3”. EMA and FDA records identify mecasermin/Increlex as the approved IGF-1 medicine reviewed here; that different 70-aa product does not authorise LR3. No approved IGF-1 LR3 product or regulator-approved regimen was identified.

Country-specific rules for possession, import, supply and human-use intent were not inferred from approval status, so the legal matrix remains unclear pending jurisdiction-by-jurisdiction review.

For sport, the classification is explicit. The 2026 WADA Prohibited List includes “Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues” under S2.3, Growth Factors and Growth Factor Modulators. The class is prohibited at all times, in and out of competition.

PeptideGuide claims under review

Bottom line

IGF-1 LR3 is a well-defined laboratory analogue with credible structural and preclinical biology. That is not the same as a clinically validated medicine. Current evidence does not establish human muscle hyperplasia, hypertrophy, a 20–30-hour half-life, a microgram regimen, product identity or long-term safety. It must not be confused with mecasermin, and it is prohibited in sport under WADA S2.3.